Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis.

Autor: Badulescu S; Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, ON, Canada., Le GH; Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, ON, Canada., Wong S; Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada., Kwan ATH; Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada., Guo Z; Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada., Teopiz KM; Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada., Phan L; Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Subramaniapillai M; Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada., Rosenblat JD; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Mansur RB; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada., McIntyre RS; Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada. roger.mcintyre@bcdf.org.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. roger.mcintyre@bcdf.org.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. roger.mcintyre@bcdf.org.
Jazyk: angličtina
Zdroj: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2024 Apr; Vol. 45 (4), pp. 1335-1342. Date of Electronic Publication: 2024 Feb 07.
DOI: 10.1007/s10072-024-07377-z
Abstrakt: Introduction: Fatigue is a prominent symptom in post-COVID condition (PCC) sequelae, termed "long COVID." Herein, we aim to ascertain the effect of fatigue on psychosocial function in persons living with PCC.
Methods: This post hoc analysis evaluated the effects of vortioxetine on measures of fatigue as assessed by the Fatigue Severity Scale (FSS) in psychosocial function as measured by the Sheehan Disability Scale (SDS) in persons with PCC. We also evaluated the change in FSS on psychosocial functioning as measured by the Sheehan Disability Scale (SDS). This post hoc analysis obtained data from a recently published placebo-controlled study evaluating vortioxetine's effect on objective cognitive functions in persons living with PCC.
Results: One hundred forty-four participants meeting World Health Organization (WHO) criteria for PCC were included in this analysis. At the end of 8 weeks of vortioxetine treatment, significant improvement of all domains was observed for psychosocial functioning. There was a significant between-group difference at treatment endpoint in the family, social, and work SDS subcategories (p < 0.001). There was a statistically significant interaction effect between the treatment condition time point and FSS effect on the SDS social (χ 2 = 10.640, p = 0.014) and work (χ 2 = 9.342, p = 0.025) categories but a statistically insignificant effect on the family categories ((χ 2 = 5.201, p = 0.158)).
Discussion: This post hoc analysis suggests that vortioxetine treatment significantly improves psychosocial function in persons with PCC. Our results also indicate that the improvement in psychosocial function was significantly mediated by improvement in measures of fatigue. Our results provide empirical support for recommendations to identify therapeutics for fatigue in persons living with PCC with a broader aim to improve psychosocial function in this common and severely impaired population.
(© 2024. Fondazione Società Italiana di Neurologia.)
Databáze: MEDLINE
Externí odkaz: